BPC-157 Use Has Exploded 33-Fold Since 2020. What Is Driving the “Wolverine” Peptide Boom?

An experimental peptide with no FDA-approved medical use has become increasingly visible in American healthcare records.

In September 2026, researchers at health data company nference published an analysis identifying 1,039 patients with documented BPC-157 use across a network of 15.2 million patient records.

The number of newly documented users per quarter increased approximately 33-fold between early 2020 and early 2026.

The findings offer an unusually detailed look at the growing interest in BPC-157, commonly nicknamed the "Wolverine peptide" because of its reputation for accelerating recovery from injuries.

But the research reveals something more complicated than a straightforward success story.

Patients reported using BPC-157 for chronic pain, gastrointestinal conditions, sports injuries and post-surgical recovery. Some described improvements. Others reported adverse effects or stopped using it after medical advice.

Meanwhile, the FDA has received ten serious adverse-event reports involving people using BPC-157 since 2021, according to a September 15 Reuters investigation.

The central question is no longer whether BPC-157 has attracted significant interest.

It is why an experimental compound is becoming more widely used before researchers have established whether it provides meaningful clinical benefits in humans.

The available evidence points to several overlapping factors: demand for relief from persistent pain and injuries, encouraging animal research, social media promotion, growing access through peptide vendors and compounding pharmacies, and renewed regulatory attention.

The new study provides evidence of these trends, particularly the reasons patients give for using BPC-157 and the channels through which they obtain it.

However, it does not establish which factor caused the increase or how much each contributed.

The 33-fold figure also needs careful interpretation. It describes an increase in newly documented users within a specific healthcare database, not a verified 33-fold increase in everyone using BPC-157 across the United States.

That distinction matters throughout this story.

The study, titled Rising Use of Unapproved BPC-157 ("Wolverine Peptide") and Associated Patient-Reported Outcomes Curated from Clinical Notes, was posted on September 7, 2026.

It is a preprint, meaning it had not undergone formal peer review at publication.

Researchers analysed de-identified electronic health records from a network containing 15.2 million patients who had at least one clinical note between 2020 and 2026.

Because BPC-157 is not an approved medicine, its use is difficult to identify through ordinary prescription records.

The researchers instead examined clinicians' written notes, using a large language model to distinguish patients who had actually used BPC-157 from those whose records merely mentioned it.

Physicians reviewed samples of the extracted information to assess the system's accuracy.

The findings provide a picture of documented use, rather than a population-wide survey.

The study's most important numbers

Source: nference study, September 2026.

The increase from four to 134 newly documented users per quarter is substantial.

Nevertheless, there are important limitations.

The study began with a very small number of identified users in 2020. A large relative increase can therefore occur without demonstrating that the same growth rate applies to the broader population.

The researchers also found that, among 80 patients with sufficiently clear information about when they started BPC-157, use began an average of 60 days before the first clinical note documenting it.

This means the date someone first appears in a medical record is not necessarily the date they began using the peptide.

The study establishes that documented BPC-157 use increased sharply within the analysed healthcare network. It cannot establish the actual number of Americans using the compound.

The clearest finding about why people use BPC-157 comes from the conditions recorded in their medical notes.

Researchers identified a specific reason for use in 644 patients.

Pain was the most frequently documented reason, appearing in 338 patients, approximately 33% of the entire study cohort.

Gastrointestinal conditions accounted for 148 patients, while 118 had a documented history of injury and 107 were using it in connection with post-surgical healing.

Performance enhancement was documented in 42 patients.

These categories were not mutually exclusive.

Source: nference clinical-note analysis.

The gastrointestinal conditions included reflux, inflammatory bowel disease and gastritis.

Among patients with documented musculoskeletal injuries, commonly affected areas included the shoulder, knee, back, elbow and hip.

These findings challenge the idea that BPC-157 is exclusively a bodybuilding or athletic-performance trend.

In this healthcare-record sample, pain and gastrointestinal complaints were documented more frequently than performance enhancement.

That does not establish that the compound works for these conditions.

It establishes what patients hoped to achieve by using it.

Someone living with persistent tendon pain, for example, may be interested in a substance promoted for tissue repair even though the supporting human evidence is limited.

The distinction between a treatment's appeal and its demonstrated effectiveness is central to understanding the boom.

BPC-157 is a synthetic peptide consisting of 15 amino acids. Its development traces back to research involving protective compounds associated with gastric tissue.

Its popular nickname comes from the fictional character Wolverine, whose defining abilities include rapid recovery from injuries.

That comparison reflects the peptide's marketing reputation, not a medically established effect in humans.

Laboratory and animal studies have investigated BPC-157 in models involving tendon injuries, ligament damage, muscle injury and gastrointestinal tissue.

Some studies have reported improvements in tissue repair and biological processes associated with healing.

Researchers have also investigated mechanisms involving blood-vessel formation, inflammatory signalling and cellular responses to injury.

These observations provide a scientific rationale for further investigation.

They do not demonstrate that BPC-157 accelerates recovery in people.

A May 2026 review published in Pharmaceutics examined BPC-157's pharmaceutical development and clinical evidence.

The authors reported that available clinical data involved fewer than 30 participants across three uncontrolled pilot studies.

They also identified major gaps in pharmaceutical formulation, human pharmacokinetics and clinical development.

No completed Phase II clinical trial was identified in that review.

Source: BPC-157 as an Investigational Peptide Therapeutic, Pharmaceutics, 2026.

The difference between promising animal results and demonstrated human benefits is not a technicality.

A compound may produce measurable biological effects in laboratory animals yet fail to provide clinically useful benefits in people.

Human trials are needed to establish whether the observed effects translate into meaningful improvements in pain, function, injury recovery or disease outcomes.

BPC-157 has become a familiar name in online fitness, biohacking and wellness discussions.

It is frequently promoted through testimonials describing improvements in joint pain, muscle recovery and digestive symptoms.

The peptide is also commonly discussed alongside TB-500 in a combination marketed as the "Wolverine stack".

A September 15, 2026, Reuters investigation identified social media promotion and claims about injury recovery and muscle growth as important features of the emerging BPC-157 market.

The difficulty is that a testimonial cannot isolate the effect of the peptide.

An injury may improve naturally over time. A person may also be receiving physiotherapy, using other medications or changing their activity levels.

The nference study illustrates precisely this problem.

Of the 1,039 documented BPC-157 users, 525, or 50.5%, had documented co-use of at least one other therapeutic agent.

Testosterone was documented in 177 patients, nonsteroidal anti-inflammatory drugs in 153, TB-500 in 134 and corticosteroids in 122.

Physical therapy was documented in 159 patients, while 131 had undergone surgery.

These overlapping interventions make it difficult to determine whether any improvement resulted from BPC-157 itself.

They also help explain why social media accounts of recovery cannot substitute for controlled clinical studies.

Another important finding concerns where patients obtained BPC-157.

Researchers could identify a consumer supply source for 205 patients, representing approximately one-fifth of the confirmed-use cohort.

Among those patients, 74 reported obtaining it from compounding pharmacies and 71 from gray-market peptide vendors.

Wellness clinics, retail outlets and online or telehealth vendors accounted for smaller shares.

Compounding pharmacies and gray-market vendors therefore represented approximately 71% of the 205 patients with an identified consumer source.

However, the source was not established for most participants, so those proportions should not be treated as representative of all BPC-157 users.

The distinction between supply channels is also important.

Pharmaceutical compounding, where legally permitted, involves preparing medications for particular medical needs under applicable requirements.

Gray-market products may be sold outside conventional medicine distribution systems, sometimes under labels stating that they are intended for research rather than human consumption.

Neither the availability of a compounded preparation nor a research-use label establishes FDA approval, pharmaceutical equivalence or clinical effectiveness.

The FDA has raised concerns about BPC-157's potential immunogenicity, peptide-related impurities and the difficulty of adequately characterising the active pharmaceutical ingredient.

These issues complicate attempts to assess the safety of products obtained outside an established drug-approval framework.

Source: FDA information on bulk drug substances presenting potential safety risks.

In July 2026, BPC-157 was considered by the FDA's Pharmacy Compounding Advisory Committee.

The committee reviewed BPC-157 free base and BPC-157 acetate for possible inclusion on the list of bulk drug substances that may be used in pharmacy compounding under Section 503A of the Federal Food, Drug, and Cosmetic Act.

The medical use evaluated was ulcerative colitis.

The committee voted in favour of recommending BPC-157 for inclusion.

However, an advisory committee recommendation is not FDA approval.

The FDA had not issued a final decision on the compounding question as of the September 15 Reuters report.

In its scientific evaluation presented to the committee, FDA staff had reached a different conclusion, recommending against inclusion.

The agency cited inadequate physicochemical characterisation, limited information about historical compounding use, insufficient safety information and unresolved immunogenicity risks.

It also concluded that the available evidence was insufficient to establish effectiveness for ulcerative colitis.

These are distinct regulatory questions.

A decision allowing a substance to be used in certain compounded preparations would not be equivalent to approving it as a safe and effective medicine for injury recovery, digestive disorders or any other indication.

Sources: FDA advisory committee meeting information and FDA scientific evaluation.

One of the most attention-grabbing findings in the new analysis concerns patient-reported outcomes.

Of the 1,039 confirmed users, researchers could determine the direction of symptom changes for 354 patients.

Among this smaller group:

• 279 patients, or 78.8%, had documented improvement.
• 58 patients, or 16.4%, had no documented change.
• 17 patients, or 4.8%, had documented worsening.

The improvement figure requires particular care.

It does not mean that BPC-157 was effective in approximately 79% of everyone who used it.

A symptom-response direction was unavailable for 685 patients, nearly two-thirds of the study cohort.

Furthermore, 263 of the 279 documented improvements were patient-reported. Only 16 were recorded solely as clinician-observed improvements.

Patient experience is valuable information, particularly when studying pain and quality of life.

But this study did not include a placebo group, an untreated comparison group or standardised objective measurements of recovery.

The investigators also could not reliably assess product quantities or adherence.

They explicitly stated that the findings cannot establish efficacy or distinguish the effects of BPC-157 from other therapies, natural recovery, placebo effects and reporting biases.

The evidence supports a narrower conclusion: some patients told their healthcare providers that their symptoms improved while using BPC-157.

Whether the peptide caused those improvements remains unknown.

The increase in documented use comes alongside emerging safety reports.

According to Reuters, the FDA's Adverse Event Monitoring System contained ten reports involving people who experienced adverse events while using BPC-157 between 2021 and September 2026.

All ten were classified as serious, and eight were reported in 2026.

These reports are separate from the nference study's clinical-note findings.

An adverse-event report does not establish that a product caused the reported medical problem.

Reports may be submitted by patients, healthcare professionals or manufacturers, and the FDA cautions that the information is not necessarily verified.

Without knowing how many people have used BPC-157, the number of reports also cannot establish the incidence of serious adverse effects.

Nevertheless, the reports warrant attention because the compound has not undergone the large-scale controlled human studies ordinarily needed to characterise a medicine's safety.

What side effects appeared in the medical-record study?

The nference researchers separately identified several categories of adverse events documented during BPC-157 use.

Neurological and psychiatric symptoms included reports such as mood changes, anxiety, insomnia and headaches.

Gastrointestinal symptoms included nausea and vomiting.

The researchers warned that adverse events were likely underreported.

These percentages describe symptoms documented in clinical notes. They are not reliable estimates of the true frequency of adverse effects among all BPC-157 users.

The clinical notes also cannot reliably separate reactions to BPC-157 from those potentially involving other treatments, formulations or underlying medical conditions.

Among 129 patients with documented discontinuation, 59 stopped following clinician advice, 24 cited adverse effects and 21 cited perceived ineffectiveness.

These findings demonstrate that negative experiences and medical concerns were documented alongside reports of improvement.

They do not establish a complete safety profile.

For readers wanting to understand the distinction between an ordinary adverse reaction and a potentially serious complication, our related coverage explores when peptide side effects require medical attention.

BPC-157's growing popularity has brought together several kinds of evidence that are often treated as though they carry equal weight.

They do not.

The 2026 nference study belongs in the observational category.

Its contribution is to show how BPC-157 is being used in real-world clinical settings, not to demonstrate that it works.

The headline figure is compelling, but it comes with several methodological limitations.

First, the researchers examined patients whose use appeared in healthcare records. People who obtained BPC-157 without discussing it with a clinician could not be reliably identified.

Second, the investigators used an AI-assisted process to extract information from written notes. Although physicians reviewed samples of the results, the system was not perfectly accurate.

Its physician-validated accuracy for distinguishing confirmed BPC-157 use from other mentions was approximately 87%.

Third, the researchers did not conduct a nationally representative survey.

The study population was also demographically distinctive.

Among patients with recorded race, 95.9% of identified users were White, compared with 78% of the background healthcare population.

The proportion of newly documented users who were male increased from 57% in 2020 to 70% in 2026, while average age decreased from 55 to 49 years.

Those figures describe patients identified within the analysed network. They cannot automatically be generalised to all Americans using BPC-157.

Finally, the authors were employees of nference, the company that conducted the analysis. The paper reported no external funding and disclosed the company's research collaborations with biopharmaceutical businesses.

These considerations do not invalidate the findings.

They explain why the study is a useful early measurement of an emerging pattern rather than a definitive picture of national use.

The next scientific step is not simply to collect more testimonials.

Researchers need controlled human studies designed to answer specific clinical questions.

For musculoskeletal injuries, that could involve measuring pain, validated functional outcomes and objective evidence of tissue recovery.

For gastrointestinal conditions, trials would need to assess disease-specific outcomes rather than relying solely on general reports of feeling better.

Before larger efficacy trials, fundamental questions about formulation, pharmacokinetics, product consistency and human tolerability also need to be addressed.

The 2026 Pharmaceutics review identified these pharmaceutical-development gaps as substantial barriers to clinical translation.

The growing number of people reporting BPC-157 use may increase the urgency of studying it.

It does not reduce the standard of evidence required to establish that a treatment is safe and effective.

Has BPC-157 use really increased 33-fold?

The September 2026 nference analysis found an approximately 33-fold increase in newly documented quarterly users within its healthcare-record network, from four in the first quarter of 2020 to 134 in the first quarter of 2026.

It did not establish a 33-fold increase in all US users.

Why is BPC-157 called the Wolverine peptide?

The nickname refers to the fictional character Wolverine and his rapid healing abilities.

It reflects BPC-157's reputation for tissue recovery, which is based largely on preclinical research and promotional claims rather than established human clinical effectiveness.

What are people using BPC-157 for?

In the 2026 study, the most frequently documented reasons included pain, gastrointestinal conditions, previous injuries and post-surgical healing.

Performance enhancement was also reported, but it was less frequently documented than those medical complaints.

None of these uses is FDA-approved.

Does the new study prove BPC-157 works?

No.

The study identified patient-reported experiences without a placebo group, untreated comparator or standardised objective outcome assessments.

It was not designed to establish treatment effectiveness.

Did 79% of BPC-157 users experience improvement?

Not across the full study population.

Approximately 79% of the 354 patients with an assessable symptom-response direction had documented improvement.

For the remaining 685 patients, the researchers could not determine the direction of symptom change.

Even among those reporting improvement, the study cannot establish that BPC-157 caused it.

What are the known side effects of BPC-157?

The new analysis identified documented neurological or psychiatric symptoms, injection-site hypersensitivity reactions and gastrointestinal symptoms.

However, the true frequency, severity and causal relationship of these events remain uncertain because comprehensive human safety studies are lacking.

Is BPC-157 FDA-approved in 2026?

No.

As of September 2026, BPC-157 was not FDA-approved for any medical indication.

An FDA advisory committee recommended its inclusion on a pharmacy-compounding bulk substances list in July 2026, but that recommendation was not equivalent to drug approval, and a final FDA decision on the compounding question remained pending as of the September 15 Reuters report.

Is the Wolverine stack scientifically proven?

No.

The term commonly refers to combining BPC-157 with TB-500.

The nference study documented TB-500 co-use in 134 BPC-157 patients, but did not test whether the combination improved outcomes.

Controlled clinical evidence establishing the effectiveness and safety of that combination remains lacking.

The most important finding in the new BPC-157 research is not simply that documented use increased 33-fold.

It is that patients are increasingly turning to an experimental compound for problems ranging from chronic pain to gastrointestinal disease while fundamental questions about its effectiveness and safety remain unanswered.

The study identifies 1,039 documented users, reveals where some patients obtain BPC-157 and shows that a subset report symptom improvements.

It also identifies adverse-event reports, widespread use alongside other therapies and substantial gaps in clinical documentation.

The evidence suggests that interest in BPC-157 extends beyond performance enhancement into broader attempts to manage persistent health problems.

But popularity, patient-reported improvement and encouraging animal research are not interchangeable with proof of clinical benefit.

The Wolverine peptide boom is now measurable.

Whether BPC-157 can fulfil the expectations driving that boom remains a question for rigorous human clinical trials.

1. nference researchers (2026). Rising Use of Unapproved BPC-157 ("Wolverine Peptide") and Associated Patient-Reported Outcomes Curated from Clinical Notes. Preprints.org, September 7, 2026. Read the original study.

1. Reuters (2026). Use of untested 'Wolverine' peptide backed by US Health Secretary Kennedy on the rise, study finds. September 15, 2026. Read the investigation.

1. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Read the FDA safety information.

1. U.S. Food and Drug Administration (2026). July 23–24, 2026: Meeting of the Pharmacy Compounding Advisory Committee. Read the official meeting information.

1. Mateescu DM et al. (2026). BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers. Pharmaceutics, 18(5), 625. Read the peer-reviewed review on PubMed.

Medical Disclaimer

This article is for educational and research-information purposes only. It does not provide medical advice, diagnosis or treatment recommendations. BPC-157 is an experimental peptide that has not been approved by the FDA for human therapeutic use. Its clinical effectiveness and safety have not been established through adequately controlled human trials. Consult a qualified healthcare professional about personal medical decisions.